Results 71 to 80 of about 181,481 (200)

One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan

open access: yesScientific Reports
This multicentre retrospective study evaluated the 1-year outcomes and safety profile of faricimab in treatment-naïve patients with neovascular age-related macular degeneration (nAMD).
Ryo Mukai   +21 more
doaj   +1 more source

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

open access: yesInternational Journal of Retina and Vitreous
Background Intravitreal faricimab, a bispecific antibody targeting both angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), was recently introduced for the treatment of neovascular age-related macular degeneration (nAMD), diabetic ...
Gabriela Grimaldi   +5 more
doaj   +1 more source

Association Between Visual Acuity and Fluid Compartments with Treat-and-Extend Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis [PDF]

open access: gold, 2022
Varun Chaudhary   +9 more
openalex   +1 more source

Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: 1-Year Outcomes. [PDF]

open access: yesInvest Ophthalmol Vis Sci, 2023
Trejo Corona S   +8 more
europepmc   +1 more source

Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease

open access: hybrid, 2019
Peter J. Kertes   +6 more
openalex   +1 more source

Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial) [PDF]

open access: bronze, 2018
Rakesh Popat   +11 more
openalex   +1 more source

Home - About - Disclaimer - Privacy